News

Myovant Sciences and Pfizer Receive FDA Approval of MYFEMBREE, a Once-Daily Endometriosis Treatment

Myovant Sciences and Pfizer have announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months. The approval is supported by one-year efficacy and safety data,…

What’s New in Femtech This Week? (Aug 11, 2022)

Every Thursday we send out a curated newsletter on “all things femtech and women’s health innovation”. This is the latest edition. If you’re interested in subscribing, you can do so at the bottom of this page. Highlights Nanopath raises $10M in Series A funding to develop and commercialize point-of-care diagnostics for women’s health. GoStork launches the first customizable fertility clinic marketplace. Breastfeeding app LatchAid reveals the results of its first trial…

Nanopath Raises $10M in Series A Funding to Develop and Commercialize Point-of-Care Diagnostics for Women’s Health

 Nanopath, a molecular diagnostics company enabling high-quality molecular testing in minutes, has raised $10M in Series A funding, co-led by Norwest Venture Partners and the Medtech Convergence Fund. Other participants in the round include Gingerbread Capital and Green D Ventures. The new funds will support development and commercialization of Nanopath’s biosensing platform that aims to transform how women’s pelvic and gynecologic infections are diagnosed. Amogha…

Breastfeeding App LatchAid Reveals the Results of Its First Trial in Collaboration with the NHS

Since launching in July 2021, LatchAid, the breastfeeding and early parenthood support application, has gained more than 7,000 users across 94 countries. Early results have now shown that mothers who are using the app are more likely to continue breastfeeding for longer. A six-month NHS trial found that, amongst the 271 UK-based survey respondents using the app, 49% were exclusively breastfeeding at 6-8…

IVF Specimen Management: CCRM Fertility and TMRW Life Sciences Expand Their Partnership

CCRM Fertility, a global pioneer in fertility treatment, research and science, announced today it will expand its partnership with TMRW Life Sciences from its initial launch clinic in Colorado to all its in vitro fertilization (IVF) laboratories across North America. By bringing digital tracking, automation and 24/7 remote monitoring to a system that has long relied on manual, in-person work by embryologists, TMRW’s technology will enable CCRM…

Nike Adds a Maternity Training Program to Its App

With all the mental and physical changes that occur during pregnancy, it’s no wonder why many pregnant people give up the dumbbells for a while. But to help keep them active, Nike is now launching its new (M)ove Like A Mother exercise program on its Training Club app. Consisting of 24 workout trainings, the program covers strength training, cardio, mobility, and yoga…

Femtech Trendwatch: World Breastfeeding Week, Autoimmune Disease & Startup Spotlight

Every Monday we share a quick “best of” from the week that was with our Inner Circle members. What’s trending in the Femtech Insider community and beyond? We’ve got you covered! In this week’s brief we talk about… Spotlight: Autoimmune Disease World Breast Feeding Week Startup Spotlight: OMAD, Germie & Binyoh And more! Spotlight: Autoimmune Disease A couple of days ago Mymee, a precision health and nutrition…

What’s New in Femtech This Week? (August 4, 2022)

Every Thursday we send out a curated newsletter on “all things femtech and women’s health innovation”. This is the latest edition. If you’re interested in subscribing, you can do so at the bottom of this page. “The Ovum Wand launch reinforces Mira’s goal to support women throughout their lives by helping them understand their hormones at any age, be it puberty, adulthood,…